MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.

Cancer Sci · 2024 · PMC11447881 · PMID 39080996

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

borderline significancep = 0.066so close (0.05 < p ≤ 0.1)

Among 14 patients with radiologically measurable lesions, the objective response rate was higher in the MGMT no/low‐expression group (50.0%) than in the MGMT intermediate/high‐expression group with borderline significance (0%, p = 0.066).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.